Abstract:Background: Nonalcoholic fatty liver disease (NAFLD) is a major factor in the pathogenesis of type-2 diabetes (T2D). Liver pyruvate kinase (PK) inactivating mutations are associated with diabetes in human subjects and PK deficiency associated with severe liver dysfunction and fat accumulation. Aim: To determine whether small molecule activators of PK (PKa) could improve liver metabolism in rats fed a high fat diet. Methods: Sprague Dawley regular chow (RC) or high fat diet (HFD) rats were either treated acutely (IV bolus 11mg/kg/min then primed continuous 0.06 mg/kg/min) or chronically (50 mg/kg/day x 3 weeks). Insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp studies. Results: PKa dose dependently suppressed glucose production from primary rat hepatocytes. Acute PKa infusion suppressed endogenous glucose production (EGP) by 20% in RC rats. Chronic PKa exposure did not affect body weight in HFD-fed rats. Three-week PKa treatment did not change activity, food intake, whole-body energy expenditure, or body weight in HFD-fed mice. Nevertheless, PKa improved whole-body insulin sensitivity compared with control HFD-fed rats (glucose infusion rate: control 11.8±1.4 vs. PKa 15.3±0.7 mg/(kg-min), P<0.05). Differences in whole-body insulin sensitivity were accounted for by a 15% reduction in EGP and increased insulin-stimulated peripheral glucose uptake (21.2±0.6 vs. 26.4±1.7 mg/(kg-min), P<0.05). Insulin-stimulated hepatic AKT phosphorylation was also significantly improved. Consistent with improving of peripheral insulin sensitivity, liver and muscle triglyceride content (liver: 27.2±2.6 vs. 16.9±1.5 mg/g, P<0.05. muscle: 9.8 ±1.4 vs. 6.7±1.0 mg/g, P<0.05) were improved in PKa-treated rats. In conclusion, activation of pyruvate kinase in rodents protects against HFD-induced insulin resistance. By reducing EGP and insulin resistance, activation of PK may be an exciting potential therapeutic target for T2D. Disclosure A. Abulizi: None. R.L. Cardone: None. S. Siebel: None. C. Kung: Employee; Self; Agios Pharmaceuticals. Stock/Shareholder; Self; Agios Pharmaceuticals. R. Kibbey: None. Funding American Diabetes Association (1-16-IBS-158 to R.K.); National Institutes of Health (R01DK108283-01A1)

32-OR: Coordination of Mitochondrial Uncoupling with Pyruvate Dehydrogenase Activation Safely Ameliorates Hyperglycemia through Preferential Glucose Oxidation

Mitochondrial Uncoupling Coordinated With Pdh Activation Safely Ameliorates Hyperglycemia Via Promoting Glucose Oxidation

PKM2-mediated Neuronal Hyperglycolysis Enhances the Risk of Parkinson's Disease in Diabetic Rats

Reversal of Hypertriglyceridemia, Fatty Liver Disease, and Insulin Resistance by a Liver-Targeted Mitochondrial Uncoupler.

Compartmentally scavenging hepatic oxidants through AMPK/SIRT3-PGC1 axis improves mitochondrial biogenesis and glucose catabolism

Controlled-release Mitochondrial Protonophore Reverses Diabetes and Steatohepatitis in Rats.

Increasing Pyruvate Dehydrogenase Flux as a Treatment for Diabetic Cardiomyopathy: A Combined 13C Hyperpolarized Magnetic Resonance and Echocardiography Study

N-p-coumaroyloctopamine ameliorates hepatic glucose metabolism and oxidative stress involved in a PI3K/AKT/GSK3β pathway

Targeting the PDK/PDH Axis to Reverse Metabolic Abnormalities by Structure-Based Virtual Screening with in Vitro and in Vivo Experiments.

DPHC From Alpinia officinarum Ameliorates Oxidative Stress and Insulin Resistance via Activation of Nrf2/ARE Pathway in db/db Mice and High Glucose-Treated HepG2 Cells

High-Throughput Assay for Modulators of Mitochondrial Membrane Potential Identifies a Novel Compound with Beneficial Effects on Db/db Mice

Hyperpolarized NMR study of the impact of pyruvate dehydrogenase kinase inhibition on the pyruvate dehydrogenase and TCA flux in type 2 diabetic rat muscle

Diosgenin Targets CaMKK2 to Alleviate Type II Diabetic Nephropathy through Improving Autophagy, Mitophagy and Mitochondrial Dynamics

DW14006 as a Direct AMPK Activator Ameliorates Diabetic Peripheral Neuropathy in Mice

120-LB: Small Molecule Activator of Pyruvate Kinase Regulates In Vivo Glucose Homeostasis

Activation of PPARδ up-regulates fatty acid oxidation and energy uncoupling genes of mitochondria and reduces palmitate-induced apoptosis in pancreatic β-cells

Sustained-release Mitochondrial Protonophore Reverses Nonalcoholic Fatty Liver Disease in Rats

Effect of CAPE-pNO2 Against Type 2 Diabetes Mellitus Via the AMPK/GLUT4/ GSK3β/PPARα Pathway in HFD/STZ-induced Diabetic Mice.

Dihydromyricetin improves high glucose induced dopaminergic neuronal damage by activating AMPK-autophagy signaling pathway

Interplay Between H6PDH and 11Β-Hsd1 Implicated in the Pathogenesis of Type 2 Diabetes Mellitus.

4-O-methylhonokiol Ameliorates Type 2 Diabetes-Induced Nephropathy in Mice Likely by Activation of AMPK-mediated Fatty Acid Oxidation and Nrf2-mediated Anti-Oxidative Stress.